AstraZeneca ends Certriad development with Abbott; Gilead drops ambrisentan in IPF
Anglo-Swedish drug major AstraZeneca (LSE: AZN) last evening notified its partner Abbott Laboratories (NYSE: ABT) that it will discontinue the development of Certriad (rosuvastatin calcium and fenofibric acid), which was being investigated for the treatment of mixed dyslipidemia. This means the co-development and license agreement with Abbott will end on 22 January 22, 2011.
Rosuvastatin is the active ingredient of AstraZeneca’s blockbuster cholesterol lowerer Crestor, and fenofibric acid is marketed by Abbott as TriLipix.
A Complete Response Letter (CRL) for the Certriad New Drug Application, which had been filed June 2009, was received from the US Food and Drug Administration earlier this year, when it already sent out warning signals about the future of the combination product that had been touted as achieving peak sales of around $500 million (The Pharma Letter March 31).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze